Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 681

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Abciximab Facilitates the Rate and Extent of Thrombolysis: Results of the Thrombolysis In Myocardial Infarction (TIMI) 14 Trial

Open access
Antman, Elliott M., Giugliano, Robert P., Gibson, C. Michael, McCabe, Carolyn H., Coussement, Patrick, Kleiman, Neal S., Vahanian, Alec, Adgey, A. A. Jennifer, Menown, Ian, Rupprecht, Hans-Jürgen, Van der Wieken, R., Ducas, John, Scherer, Joel, Anderson, Keaven, Van de Werf, Frans, Braunwald, Eugene·1999·Circulation

Abstract

Background —The TIMI 14 trial tested the hypothesis that abciximab, the Fab fragment of a monoclonal antibody directed to the platelet glycoprotein (GP) IIb/IIIa receptor, is a potent and safe addition to reduced-dose thrombolytic regimens for ST-segment elevation MI. Methods and Results —Patients (n=888) with ST-elevation MI presenting <12 hours from onset of symptoms were treated with aspirin and randomized initially to either 100 mg of accelerated-dose alteplase (control) or abciximab (bolus 0.25 mg/kg and 12-hour infusion of 0.125 μg · kg −1 · min −1 ) alone or in combination with reduced doses of alteplase (20 to 65 mg) or streptokinase (500 000 U to 1.5 MU). Control patients received standard weight-adjusted heparin (70-U/kg bolus; infusion of 15 U · kg −1 · h −1 ), whereas those treated with a regimen including abciximab received low-dose heparin (60-U/kg bolus; infusion of 7 U · kg −1 · h −1 ). The rate of TIMI 3 flow at 90 minutes for patients treated with accelerated alteplase alone was 57% compared with 32% for abciximab alone and 34% to 46% for doses of streptokinase between 500 000 U and 1.25 MU with abciximab. Higher rates of TIMI 3 flow at both 60 and 90 minutes were observed with increasing duration of administration of alteplase, progressing from a bolus alone to a bolus followed by either a 30- or 60-minute infusion ( P <0.02). The most promising regimen was 50 mg of alteplase (15-mg bolus; infusion of 35 mg over 60 minutes), which produced a 76% rate of TIMI 3 flow at 90 minutes and was tested subsequently in conjunction with either low-dose or very-low-dose (30-U/kg bolus; infusion of 4 U · kg −1 · h −1 ) heparin. TIMI 3 flow rates were significantly higher in the 50-mg alteplase plus abciximab group versus the alteplase-only group at both 60 minutes (72% versus 43%; P =0.0009) and 90 minutes (77% versus 62%; P =0.02). The rates of major hemorrhage were 6% in patients receiving alteplase alone (n=235), 3% with abciximab alone (n=32), 10% with streptokinase plus abciximab (n=143), 7% with 50 mg of alteplase plus abciximab and low-dose heparin (n=103), and 1% with 50 mg of alteplase plus abciximab with very-low-dose heparin (n=70). Conclusions —Abciximab facilitates the rate and extent of thrombolysis, producing early, marked increases in TIMI 3 flow when combined with half the usual dose of alteplase. This improvement in reperfusion with alteplase occurred without an increase in the risk of major bleeding. Substantial reductions in heparin dosing may reduce the risk of bleeding even further. Modest improvements in TIMI 3 flow were seen when abciximab was combined with streptokinase, but there was an increased risk of bleeding.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/01.cir.99.21.2720

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 29 references

Cited by

See all 681

Metadata

Authors
Antman, E. M., Giugliano, R. P., Gibson, C. M., McCabe, C. H., Coussement, P., Kleiman, N. S., Vahanian, A., Adgey, A. A. J., Menown, I., Rupprecht, H.-J., Van der Wieken, R., Ducas, J., Scherer, J., Anderson, K., Van de Werf, F., & Braunwald, E.
Venue
Circulation
Published
1999-06
Volume
99
Issue
21
Pages
2720-2732
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
OpenAlex
W1972109636
Cited by
681
References
29
FWCI
76.05
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Abciximab Facilitates the Rate and Extent of Thrombolysis: Results of the Thrombolysis In Myocardial Infarction (TIMI) 14 Trial. https://app.cochat.ai/papers/10.1161/01.cir.99.21.2720
The paper
Antman, E. M., Giugliano, R. P., Gibson, C. M., McCabe, C. H., Coussement, P., Kleiman, N. S., Vahanian, A., Adgey, A. A. J., Menown, I., Rupprecht, H.-J., Van der Wieken, R., Ducas, J., Scherer, J., Anderson, K., Van de Werf, F., & Braunwald, E. (1999). Abciximab Facilitates the Rate and Extent of Thrombolysis: Results of the Thrombolysis In Myocardial Infarction (TIMI) 14 Trial. Circulation. https://doi.org/10.1161/01.cir.99.21.2720

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.